



CLS Selects Quest International to Provide Aftermarket Service and Logistics Operations to boost commercial expansion

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) announces today that its US subsidiary has selected Quest International, a global aftermarket technical service provider to OEMs, to provide service and logistics operations for the US market. Under the agreement, Quest will provide end to end white glove service management including field services, depot repair, and warehousing and logistics support for CLS’s soft tissue ablation system, the TRANBERG Thermal Therapy System.

The collaboration is an important part of the company's expansion strategy and means that the CLS organization can meet growing demand more efficiently.

In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men. Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.

“To partner with Quest International, given their expertise in all aspects of aftermarket service and logistics operations, is an important step in our vision to contribute to improved care and increased quality of life for cancer patients. Quest International has an excellent reputation and they will enable us to maximize our operational efficiencies meeting the strong growth and interest in the US urology market,” said Dan J. Mogren, CEO, CLS.

“Quest is excited to provide Aftermarket Service and Logistics Operations to CLS Americas while they focus on continued market expansion and commercialization of their TRANBERG Thermal Therapy System and minimally invasive prostate cancer treatment,” said Shawn Arshadi, President & CEO of Quest International.

Contact Information:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 – (0)705 – 90 11 40

E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imLT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on

the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se

About Quest International

Quest International is the leading global aftermarket service support partner for original equipment manufacturers (OEMs) across multiple industries, including healthcare, industrial, aviation, and government, as well as an IT managed services provider for businesses both large and small. Having served Fortune 500 companies since 1982, Quest is dedicated to meeting the needs of their customers with a comprehensive suite of services and solutions. Follow Quest International on LinkedIn and visit their website, www.questinc.com, for more information about what they can do for your company.